[contact-form-7 404 "Not Found"]

ABOUT NATIONAL LIVER CONFERENCE

We are dedicated to providing both a superior scientific program and an opportunity for you to network with colleagues that practice in the field of liver disease. Our exhibitors provide products and services important to the liver disease community. We strive to offer exhibitors, sponsors, and attendees ample opportunities to network throughout the meeting. Your participation is critical to the success of our event.

Pricing

Early Bird Registrations begins June 15, 2018

EARLY BIRD SPECIAL PRICING

Physicians
$275

Nurse/Fellow/Student
$200

Physician Group Rate (3 or more)
$250

Nurse/Fellow/Student Group Rate (3 or more)
$175

Agenda

View our conference agenda

7 - 8 a.m.

Registration & Breakfast

Salon A/B
8 - 8:15 a.m.

Opening Ceremonies

General Track / Advance Track
8:15 - 8:45 a.m.

General Track / Advance Track

Dr. O'Leary

Dr. Jacqueline O'Leary

Biomarkers in Liver Disease

Role of current available biomarkers in day to day practice of hepatology and transplant.
8:45 - 9:15 a.m.
Dr. Harrison

Dr. Harrison

NASH Update

General Track / Advance Track
9:15 - 10:15 a.m.
Dr. Harrison

Dr. Harrison

NASH Clinical Update

General Track / Advance Track
10:15 - 10:45 a.m.

Break

10:45 - 11:45

General Track

Dr. Richard "Todd" Stravitz

Dr. Richard "Todd" Stravitz

Coagulation Disturbances in Cirrhosis

Standard tests of coagulation suggest that patients with cirrhosis have a bleeding diathesis, which clinicians have misinterpreted as the cause of portal hypertensive bleeding and an increased risk of post-procedural bleeding. However, clinical and translational studies in the last 10 years increasingly question this perception and suggest that cirrhosis is a state of re-balanced hemostasis, slightly tipped toward hypercoagulability.
10:45 - 11:45 a.m.

General Track

Dr. Runyon

Dr. Bruce Runyon

Portal Hypertension Update

Recent developments in variceal bleeding, ascites, and coagulopathy of liver disease.

10:45 - 11:45 a.m.

Advance Track

Dr. O'Leary

Dr. Jacqueline O'Leary

Preventing Readmission

Tangible tools to prevent hospital readmission in decompensated cirrhotics. Get expert feedback on the most common reasons for readmission and ways to prevent them.
11:45 - 12:15 a.m.

General Track

Dr. Wong

Dr. Florence Wong

Treating Renal Dysfunction in Cirrhosis

Renal dysfunction in cirrhosis has a significant negative impact on patient survival and post transplant outcomes. It is important to recognize it early and initiate prompt treatment. This presentation will go over recent changes in the definition of renal dysfunction, various treatment options, their efficacy and potential treatment outcomes.
12:15 - 1:15 p.m.

Lunch

1:15 - 2:15 p.m.

General Track

Hepatitis B Virus Panel Discussion

Panel Discussion by Dr. Norah Terrault; Panel – Dr. Bob Gish and Dr. Blaine Hollinger
1:15 - 2:15 p.m.

Advance Track

Liver Transplant Panel

Cases in liver transplantation will be discussed.
Presenter: Dr. Levitsky

Case presentations of interesting transplant related issues.
Presenter: Dr. Kymberly Watt

Transplant cases
Presenter: Dr. Ajaz Ahmed

Moderator- Dr. Charlton

2:15 - 2:45 p.m.

General Track

Dr. Gish

Dr. Robert Gish

Screening for Liver Disease: Who, What and When?

Liver disease is now extremely common in the United States because of emergence of the new epidemic of fatty liver, this is overlaid on the background of alcoholic Liver disease and Viral Hepatitis C. Working up a liver tests is extremely important when abnormal. Primary care providers as well as specialist need to understand the normal and healthy range for all liver tests that are included in a normal liver panel. The work up should be cost-effective and should lead to immediate interventions that can decrease the prevalence of liver disease and are at risk population. There are six key tests for working up the most common six forms of liver disease that will be discussed. This is rapid sensitive and inexpensive. Evaluation for more unusual forms of liver seas will also be discussed. And outline of imaging over to Melanies will also be presented that should lead to specific testing.
2:15 - 2:45 p.m.

Advance Track

Dr. Friedman

Dr. Scott Friedman

Novel Anti-fibrotic Therapies

Progress in developing new therapies for fibrotic liver disease due to NASH, cholestatic liver disease, and viral hepatitis has been swift and exciting.  This lecture will review the rationale for novel antifibrotic therapies and their current state of clinical development, focusing on advances that hold the greatest promise for patients with chronic liver disease.
2:45 - 3:15 p.m.

Break

3:15 - 3:45 p.m.

General Track / Advance Track

Dr. Runyon

Dr. Bruce Runyon

Recompensation: Who, When and How Often?

Recompensation of decompensated cirrhosis is common, especially in alcoholic liver disease, decompensated hepatitis B and autoimmune hepatitis. Achieving recompensation usually prevents the need for transplant.
3:45 - 4:45 p.m.

General Track / Advance Track

Hepatitis C

Panel Discussion by Dr. Eugene Schiff; Panel: Dr. Jacqueline O’Leary, Dr. Marcella Kugelmas, Dr. Raj Reddy and Dr. Norah Terrault
4:45 - 5 p.m.

Closing Ceremonies

HOTEL ACCOMMODATIONS

Renaissance Austin Hotel

Renaissance Austin Hotel is offering a special group rate for all NLC attendees. You can book a hotel room for $165.00 per night.

Keep in mind there are limited rooms available and all rooms are first come first serve.

Pinnacle Research 2018 National Liver Conference accommodations are available for the following dates 9/20-9/22.

Last day to reserve accommodations is 8/24/18.

meet with

professionals

our speakers

Check back for additional speakers

Dr. Watt

Dr. Kymberly Watt

Dr. Reddy

Dr. Reddy

Dr. Gish

Dr. Gish

Dr. Bajaj

Dr. Jasmohan S. Bajaj

Dr. O'Leary

Dr. Jacqueline O'Leary

Dr. Frias

Dr. Juan Faris

Dr. Friedman

Dr. Scott Friedman

Dr. Konerman

Dr. Monica Konerman

Dr. Kugelmas

Dr. Marcelo Kugelmas

Dr. Runyon

Dr. Bruce Runyon

Dr. Richard "Todd" Stravitz

Dr. Richard "Todd" Stravitz

Dr. Norah Terrault

Dr. Norah Terrault

Dr. Wong

Dr. Florence Wong

Dr. Levitsky

Dr. Levitsky

Dr. Ahmed

Dr. Ajaz Ahmed

Dr. Hollinger

Dr. F. Blaine Hollinger

Dr. Charlton

Dr. Michael Charlton

Dr. Harrison

Dr. Harrison

Dr. Schiff

Dr. Schiff

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Pinnacle Clinical Research. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
All faculty and staff involved in the planning or presentation of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS} are required to disclose to the audience any real or apparent commercial financial affiliations related to the  content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Charles Willis, Director of Continuing Education, consults for Pfizer, Inc., all other staff at the Annenberg Center for Health Sciences at Annenberg and Pinnacle Clinical Research have no relationships to disclose.

Learner Assurance Statement
The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s}. The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

The opinions expressed during this live activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower. The information is presented for the purpose of advancing the attendees’ professional development.

This activity is supported by educational grants from Cirius Therapeutics, Cymabay Therapeutics, Echosens, Gilead, Intercept Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, NGM Biopharmaceuticals, Salix Pharmaceuticals and Shionogi Inc.

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Pinnacle Clinical Research, PLLC